Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings

In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet.

[1]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[2]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[3]  Minoru Yoshida,et al.  The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients. , 2011, Biological & pharmaceutical bulletin.

[4]  A. Vissink,et al.  Aging and saliva: a review of the literature. , 1996, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[5]  M. Hongo,et al.  Effect of aging on the esophageal motor functions. , 1996, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[6]  L. Slay,et al.  Pharmacokinetic and pharmacodynamic monitoring of the elderly in critical care. , 1996, Critical care nursing clinics of North America.

[7]  H. Hasselbalch,et al.  Oesophageal transit of six commonly used tablets and capsules. , 1982, British medical journal.

[8]  M. Rajaniemi,et al.  Development of a method for study of the tendency of drug products to adhere to the esophagus. , 1982, Journal of pharmaceutical sciences.